ROI of AI in Regulatory Affairs: The Metrics VPs Use to Justify the Budget

Technology conversations in regulatory affairs usually begin the same way. Someone promises fewer manual steps, shorter timelines, and better productivity. A few months later, the discussion changes. Teams want to know where the savings appeared, whether submission work actually became easier, and whether the investment changed anything beyond adding another system to manage.

Regulatory leaders are often expected to answer those questions with numbers, and that is where many business cases stall. The challenge is rarely a lack of data. Submission timelines, QC findings, publishing effort, amendment cycles, and project hours exist across trackers, spreadsheets, and project records. The issue is that the data was never collected with ROI measurement in mind.

Finance teams do not approve budgets because a process feels more efficient. They look for evidence tied to cost, workload, and measurable operational change. The question is not whether AI can help regulatory teams work differently. The more practical question is whether those improvements can be measured in a way that survives budget review.

Why ROI Is Difficult to Quantify in Regulatory Affairs

Regulatory work creates value differently compared to revenue-generating functions. Teams see it when a filing moves forward without technical issues, when a review cycle avoids unnecessary rework, or when a submission stays on schedule despite competing priorities. Many of the benefits appear as costs that never materialized. A clean submission has value, but measuring it requires understanding what would have happened if the submission had required correction or amendment.

The second challenge is that savings rarely appear in a single activity. A reduction in formatting work might save hours for publishing teams. Fewer technical issues may reduce repeated QC cycles. Better document consistency can lower downstream correction work. Small gains often appear across different functions and at different stages of the process.

Teams that build stronger business cases usually start with a different question: where is work accumulating today? The answer often produces more useful information than beginning with assumptions about future savings.

The Metrics Regulatory Leaders Rely On

Four categories of measurement appear consistently in regulatory AI business cases that survive internal scrutiny. Each addresses a different cost driver and speaks to a different stakeholder concern.

Labor Hours Recovered

Labor savings are often the first metric reviewed because they are easier to connect to existing workflows. The useful approach is to look at recent submissions of the same type and examine where time was actually spent. Hours often accumulate in document preparation, repeated QC work, publishing support, hyperlink updates, and cross-reference checks following late content changes. Those activities produce a more reliable baseline than estimating savings across the total submission effort.

The calculation should use the loaded FTE cost rather than salary alone. Benefits, overhead allocation, and organizational costs can materially change the final estimate.

Submission Cycle Time

Cycle time is the interval from decision-to-submit to actual filing. Shortening it carries financial implications proportional to the program stage. For a late-stage NDA approaching approval, each day of delay has a calculable market value. For an early IND, the cost is primarily internal labor and schedule impact on connected workstreams.

Track this in days per submission type across a consistent sample. Any cycle time improvement presented in a business case should include the deficiency rate data alongside it. A submission filed faster but with more errors is not an efficiency gain. It transfers cost forward into the amendment cycle, which tends to be more disruptive than the time saved in preparation.

Rework and Deficiency Cost

Deficiency cycles are systematically undertracked because their costs accumulate across multiple teams and fiscal periods. A technical deficiency on an NDA may require 20 hours of regulatory affairs time, 10 hours of project management coordination, and 5 hours of clinical or medical input to resolve. Only the regulatory affairs portion typically appears in any budget analysis.

FDA’s guidance on refuse-to-file (RTF) actions identifies electronic submission deficiencies, including eCTD structural errors, broken hyperlinks, and missing bookmarks, as issues that can trigger an RTF action even when the application’s scientific content is complete. These are not scientific errors. There are structural and formatting problems that a validation tool can catch before submission. The ROI of catching them is the avoided cost of the rework cycle that follows when they are not.

Track deficiency volume by type over time, separating technical and formatting issues from content-related ones. Calculate average resolution hours per deficiency type. This number becomes the avoided-cost input once AI reduces deficiency rates.

Regulatory Team Capacity

Regulatory teams routinely manage submission volumes that grow faster than headcount, particularly at growth-stage biotech organizations scaling toward a first NDA or BLA. If AI tooling allows a team to absorb additional submission volume without adding headcount, the ROI includes both avoided hiring costs and the ability to advance more programs on the same schedule. This category is most relevant for teams facing projected volume growth. For those managing a fixed pipeline with no near-term expansion, the business case should reflect that honestly.

Why Pharmacovigilance Needs a Different ROI Approach

The ROI of AI in pharmacovigilance quantification does not follow the same logic as submissions work, and applying the same framework produces misleading results.

Submission work moves through defined milestones and delivery dates. Pharmacovigilance is continuous. Case volume changes over time, reporting deadlines remain fixed, and workload continues regardless of other priorities. Because of this, ROI cannot be measured only by time saved. The more useful indicators are tied to operational throughput and compliance pressure:

• ICSR processing time per case, from intake to submission
• Case backlog volume at regular intervals in the reporting cycle
• MedDRA coding accuracy
• Expedited reporting compliance against 7-day and 15-day deadlines
• Time required for PSUR and PBRER preparation

The real question is whether teams can reduce repetitive case-handling work without creating additional review burden or compliance risk downstream. Expedited reporting deadlines carry enforcement consequences. Both FDA and EMA have mechanisms for addressing late or missing ICSRs, and those consequences can extend to broader program-level scrutiny in aggregate.

Published evidence on AI in pharmacovigilance is growing but uneven. A 2025 review in Therapeutic Advances in Drug Safety found consistent potential for improving case processing throughput and signal detection, while noting that practical implementation remains constrained by data quality issues, regulatory acceptance requirements, and the need for transparent, auditable outputs. Results vary considerably by implementation context. Direct measurement against your own baseline is more defensible than extrapolating from published figures.

Factors That Can Change the Outcome of an ROI Calculation

ROI projections that look defensible on paper and disappoint in practice usually fail for predictable reasons.